Satellos Bioscience Inc

TSX:MSCLCanadaView on OTCQB

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

Contact Information

Headquarters

200 Bay Street, Suite 2800TORONTO, ON, Canada M5J 2J1

Phone

647-660-1780

Fax

---

Executives

Chairman of the Board

Geoff Mackay

President, Chief Executive Officer, Director

Frank Gleeson

Chief Financial Officer

Elizabeth Williams

Senior Vice President - Clinical Development Operations

Courtney Wells

Chief Scientific Officer

Philip Lambert